* Inari Medical Inc NARI.OQ NARI.O is expected to show a
rise
in quarterly revenue when it reports results on February 23.
* The Irvine California-based company is expected to report
a
60.8% increase in revenue to $78.158 million from $48.61 million
a year ago, according to the mean estimate from 4 analysts,
based on Refinitiv data.
* Refinitiv's mean analyst estimate for Inari Medical Inc
is for
earnings of 3 cents per share. For the same quarter last year,
the company reported earnings of 13 cents per share.
* The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 5 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Inari
Medical Inc
is $119, about 37.9% above its last closing price
of $73.86.
* Previous quarterly performance (using preferred earnings
measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Sep. 30 2021 -0.21 -0.11 -0.06 Beat 45.5
Jun. 30 2021 0.09 0.08 0.07 Missed -14.3
Mar. 31 2021 0.07 0.05 0.13 Beat 151.6
Dec. 31 2020 0.02 0.01 0.13 Beat 875.2
Sep. -0.03 -0.04 0.12 Beat 415.8
30 2020
Jun. 30 2020 -0.18 -0.18 -0.16 Beat 9.4
This summary was machine generated February 22 at 03:06 GMT.
All figures in US dollars unless otherwise stated